Search

Your search keyword '"Kinders, Robert J."' showing total 312 results
Start Over Author "Kinders, Robert J."
312 results on '"Kinders, Robert J."'

2. Interferon-gamma is quintessential for NOS2 and COX2 expression in ER- breast tumors that lead to poor outcome

Author

Cheng, Robert Y. S., Ridnour, Lisa A., Wink, Adelaide L., Gonzalez, Ana L., Femino, Elise L., Rittscher, Helene, Somasundaram, Veena, Heinz, William F., Coutinho, Leandro, Rangel, M. Cristina, Edmondson, Elijah F., Butcher, Donna, Kinders, Robert J., Li, Xiaoxian, Wong, Stephen T. C., McVicar, Daniel W., Anderson, Stephen K., Pore, Milind, Hewitt, Stephen M., Billiar, Timothy R., Glynn, Sharon A., Chang, Jenny C., Lockett, Stephen J., Ambs, Stefan, and Wink, David A.

Published
2023
Full Text
View/download PDF

3. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma

Author

Burton, Jenna H, Mazcko, Christina, LeBlanc, Amy, Covey, Joseph M, Ji, Jiuping, Kinders, Robert J, Parchment, Ralph E, Khanna, Chand, Paoloni, Melissa, Lana, Sue, Weishaar, Kristen, London, Cheryl, Kisseberth, William, Krick, Erika, Vail, David, Childress, Michael, Bryan, Jeffrey N, Barber, Lisa, Ehrhart, EJ, Kent, Michael, Fan, Timothy, Kow, Kelvin, Northup, Nicole, Wilson-Robles, Heather, Tomaszewski, Joseph, Holleran, Julianne L, Muzzio, Miguel, Eiseman, Julie, Beumer, Jan H, Doroshow, James H, and Pommier, Yves

Subjects
Rare Diseases, Orphan Drug, Cancer, Lymphoma, Clinical Research, Clinical Trials and Supportive Activities, Hematology, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Good Health and Well Being, Animals, Antineoplastic Agents, Bone Marrow, Clinical Trials as Topic, DNA Topoisomerases, Type I, Disease Models, Animal, Dogs, Drug Monitoring, Maximum Tolerated Dose, Molecular Targeted Therapy, Topoisomerase I Inhibitors, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeOnly one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved, the camptothecins with irinotecan and topotecan widely used. Because of their limitations (chemical instability, drug efflux-mediated resistance, and diarrhea), novel TOP1 inhibitors are warranted. Indenoisoquinoline non-camptothecin topoisomerase I (TOP1) inhibitors overcome chemical instability and drug resistance that limit camptothecin use. Three indenoisoquinolines, LMP400 (indotecan), LMP776 (indimitecan), and LMP744, were examined in a phase I study for lymphoma-bearing dogs to evaluate differential efficacy, pharmacodynamics, toxicology, and pharmacokinetics.Experimental designEighty-four client-owned dogs with lymphomas were enrolled in dose-escalation cohorts for each indenoisoquinoline, with an expansion phase for LMP744. Efficacy, tolerability, pharmacokinetics, and target engagement were determined.ResultsThe MTDs were 17.5 mg/m2 for LMP 776 and 100 mg/m2 for LMP744; bone marrow toxicity was dose-limiting; up to 65 mg/m2 LMP400 was well-tolerated and MTD was not reached. None of the drugs induced notable diarrhea. Sustained tumor accumulation was observed for LMP744; γH2AX induction was demonstrated in tumors 2 and 6 hours after treatment; a decrease in TOP1 protein was observed in most lymphoma samples across all compounds and dose levels, which is consistent with the fact that tumor response was also observed at low doses LMP744. Objective responses were documented for all indenoisoquinolines; efficacy (13/19 dogs) was greatest for LMP744.ConclusionsThese results demonstrate proof-of-mechanism for indenoisoquinoline TOP1 inhibitors supporting their further clinical development. They also highlight the value of the NCI Comparative Oncology Program (https://ccr.cancer.gov/Comparative-Oncology-Program) for evaluating novel therapies in immunocompetent pets with cancers.

Published
2018

4. NOS2 and COX2 Provide Key Spatial Targets that Determine Outcome in ER-Breast Cancer

Author

Ridnour, Lisa A, primary, Heinz, William F, additional, Cheng, Robert YS, additional, Wink, Adelaide L, additional, Kedei, Noemi, additional, Pore, Milind, additional, Imtiaz, Fatima, additional, Femino, Elise L, additional, Gonzalez, Ana L, additional, Coutinho, Leandro, additional, Butcher, Donna, additional, Edmondson, Elijah F, additional, Rangel, M. Cristina, additional, Kinders, Robert J, additional, Lipkowitz, Stanley, additional, Wong, Stephen TC, additional, Anderson, Stephen K, additional, McVicar, Danial W, additional, Li, Xiaoxian, additional, Glynn, Sharon A, additional, Billiar, Timothy R, additional, Chang, Jenny C, additional, Hewitt, Stephen M, additional, Ambs, Stefan, additional, Lockett, Stephen J, additional, and Wink, David A, additional

Published
2023
Full Text
View/download PDF

6. Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

Author

Coyne, Geraldine O.’Sullivan, Wang, Lihua, Zlott, Jennifer, Juwara, Lamin, Covey, Joseph M., Beumer, Jan H., Cristea, Mihaela C., Newman, Edward M., Koehler, Stephen, Nieva, Jorge J., Garcia, Agustin A., Gandara, David R., Miller, Brandon, Khin, Sonny, Miller, Sarah B., Steinberg, Seth M., Rubinstein, Larry, Parchment, Ralph E., Kinders, Robert J., Piekarz, Richard L., Kummar, Shivaani, Chen, Alice P., and Doroshow, James H.

Published
2020
Full Text
View/download PDF

7. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers

Author

Reiss, Kim A., Herman, Joseph M., Armstrong, Deborah, Zahurak, Marianna, Fyles, Anthony, Brade, Anthony, Milosevic, Michael, Dawson, Laura A., Scardina, Angela, Fischer, Patricia, Hacker-Prietz, Amy, Kinders, Robert J., Wang, Lihua, Chen, Alice, Temkin, Sarah, Horiba, Naomi, Stayner, Lee-Anne, Siu, Lillian L., and Azad, Nilofer S.

Published
2017
Full Text
View/download PDF

8. Interferon-gamma is Quintessential for NOS and COX Expression in ER- Breast Tumors that Lead to Poor Outcome

Author

Cheng, Robert YS, primary, Ridnourl, Lisa A, additional, Wink, Adelaide L, additional, Gonzalez, Ana L, additional, Femino, Elise L, additional, Rittscher, Helene, additional, Somasundarum, Venna, additional, Heinz, William F, additional, Coutinho, Leandro, additional, Rangel, Cristina, additional, Edmondson, Elijah f, additional, Butcher, Donna, additional, Kinders, Robert J, additional, Li, Xiaoxian, additional, Wong, Setphen TC, additional, McVicar, Daniel W, additional, Anderson, Stephen K, additional, Pore, Milind, additional, Hewitt, Stephen M, additional, Billiar, Timothy R, additional, Glynn, Sharon, additional, Chang, Jenny C, additional, Lockett, Stephen J, additional, Ambs, Stephen, additional, and Wink, David A, additional

Published
2023
Full Text
View/download PDF

9. Data from Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors

Author

Srivastava, Apurva K., primary, Hollingshead, Melinda G., primary, Govindharajulu, Jeevan Prasaad, primary, Covey, Joseph M., primary, Liston, Dane, primary, Simpson, Melanie A., primary, Peggins, James O., primary, Bottaro, Donald P., primary, Wright, John J., primary, Kinders, Robert J., primary, Doroshow, James H., primary, and Parchment, Ralph E., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Tables S1-S2 and Supplementary Figures S1-S6 from Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors

Author

Srivastava, Apurva K., primary, Hollingshead, Melinda G., primary, Govindharajulu, Jeevan Prasaad, primary, Covey, Joseph M., primary, Liston, Dane, primary, Simpson, Melanie A., primary, Peggins, James O., primary, Bottaro, Donald P., primary, Wright, John J., primary, Kinders, Robert J., primary, Doroshow, James H., primary, and Parchment, Ralph E., primary

Published
2023
Full Text
View/download PDF

11. Supplemental Figure S2 from Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use

Author

Srivastava, Apurva K., primary, Jaganathan, Soumya, primary, Stephen, Laurie, primary, Hollingshead, Melinda G., primary, Layhee, Adam, primary, Damour, Eric, primary, Govindharajulu, Jeevan Prasaad, primary, Donohue, Jennifer, primary, Esposito, Dominic, primary, Mapes, James P., primary, Kinders, Robert J., primary, Takebe, Naoko, primary, Tomaszewski, Joseph E., primary, Kummar, Shivaani, primary, Doroshow, James H., primary, and Parchment, Ralph E., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Methods from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Author

LoRusso, Patricia M., primary, Li, Jing, primary, Burger, Angelika, primary, Heilbrun, Lance K., primary, Sausville, Edward A., primary, Boerner, Scott A., primary, Smith, Daryn, primary, Pilat, Mary Jo, primary, Zhang, Jie, primary, Tolaney, Sara M., primary, Cleary, James M., primary, Chen, Alice P., primary, Rubinstein, Lawrence, primary, Boerner, Julie L., primary, Bowditch, Adam, primary, Cai, Dongpo, primary, Bell, Tracy, primary, Wolanski, Andrew, primary, Marrero, Allison M., primary, Zhang, Yiping, primary, Ji, Jiuping, primary, Ferry-Galow, Katherine, primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Expression Data from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Author

Kummar, Shivaani, primary, Oza, Amit M., primary, Fleming, Gini F., primary, Sullivan, Daniel M., primary, Gandara, David R., primary, Naughton, Michael J., primary, Villalona-Calero, Miguel A., primary, Morgan, Robert J., primary, Szabo, Peter M., primary, Youn, Ahrim, primary, Chen, Alice P., primary, Ji, Jiuping, primary, Allen, Deborah E., primary, Lih, Chih-Jian, primary, Mehaffey, Michele G., primary, Walsh, William D., primary, McGregor, Paul M., primary, Steinberg, Seth M., primary, Williams, P. Mickey, primary, Kinders, Robert J., primary, Conley, Barbara A., primary, Simon, Richard M., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

14. Supplemental Table S2 from Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use

Author

Srivastava, Apurva K., primary, Jaganathan, Soumya, primary, Stephen, Laurie, primary, Hollingshead, Melinda G., primary, Layhee, Adam, primary, Damour, Eric, primary, Govindharajulu, Jeevan Prasaad, primary, Donohue, Jennifer, primary, Esposito, Dominic, primary, Mapes, James P., primary, Kinders, Robert J., primary, Takebe, Naoko, primary, Tomaszewski, Joseph E., primary, Kummar, Shivaani, primary, Doroshow, James H., primary, and Parchment, Ralph E., primary

Published
2023
Full Text
View/download PDF

16. Figure S3 from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Author

Kummar, Shivaani, primary, Oza, Amit M., primary, Fleming, Gini F., primary, Sullivan, Daniel M., primary, Gandara, David R., primary, Naughton, Michael J., primary, Villalona-Calero, Miguel A., primary, Morgan, Robert J., primary, Szabo, Peter M., primary, Youn, Ahrim, primary, Chen, Alice P., primary, Ji, Jiuping, primary, Allen, Deborah E., primary, Lih, Chih-Jian, primary, Mehaffey, Michele G., primary, Walsh, William D., primary, McGregor, Paul M., primary, Steinberg, Seth M., primary, Williams, P. Mickey, primary, Kinders, Robert J., primary, Conley, Barbara A., primary, Simon, Richard M., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

17. Supplemental Materials and Methods from Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use

Author

Srivastava, Apurva K., primary, Jaganathan, Soumya, primary, Stephen, Laurie, primary, Hollingshead, Melinda G., primary, Layhee, Adam, primary, Damour, Eric, primary, Govindharajulu, Jeevan Prasaad, primary, Donohue, Jennifer, primary, Esposito, Dominic, primary, Mapes, James P., primary, Kinders, Robert J., primary, Takebe, Naoko, primary, Tomaszewski, Joseph E., primary, Kummar, Shivaani, primary, Doroshow, James H., primary, and Parchment, Ralph E., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Materials from Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays

Author

Srivastava, Apurva K., primary, Hollingshead, Melinda G., primary, Weiner, Jennifer, primary, Navas, Tony, primary, Evrard, Yvonne A., primary, Khin, Sonny A., primary, Ji, Jiuping Jay, primary, Zhang, Yiping, primary, Borgel, Suzanne, primary, Pfister, Thomas D., primary, Kinders, Robert J., primary, Bottaro, Donald P., primary, Linehan, W. Marston, primary, Tomaszewski, Joseph E., primary, Doroshow, James H., primary, and Parchment, Ralph E., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Author

LoRusso, Patricia M., primary, Li, Jing, primary, Burger, Angelika, primary, Heilbrun, Lance K., primary, Sausville, Edward A., primary, Boerner, Scott A., primary, Smith, Daryn, primary, Pilat, Mary Jo, primary, Zhang, Jie, primary, Tolaney, Sara M., primary, Cleary, James M., primary, Chen, Alice P., primary, Rubinstein, Lawrence, primary, Boerner, Julie L., primary, Bowditch, Adam, primary, Cai, Dongpo, primary, Bell, Tracy, primary, Wolanski, Andrew, primary, Marrero, Allison M., primary, Zhang, Yiping, primary, Ji, Jiuping, primary, Ferry-Galow, Katherine, primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

21. Supplemental Figure 1 from A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis

Author

Reiss, Kim A., primary, Herman, Joseph M., primary, Zahurak, Marianna, primary, Brade, Anthony, primary, Dawson, Laura A., primary, Scardina, Angela, primary, Joffe, Caitlin, primary, Petito, Emily, primary, Hacker-Prietz, Amy, primary, Kinders, Robert J., primary, Wang, Lihua, primary, Chen, Alice, primary, Temkin, Sarah, primary, Horiba, Naomi, primary, Siu, Lillian L., primary, and Azad, Nilofer S., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure Legends from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Author

LoRusso, Patricia M., primary, Li, Jing, primary, Burger, Angelika, primary, Heilbrun, Lance K., primary, Sausville, Edward A., primary, Boerner, Scott A., primary, Smith, Daryn, primary, Pilat, Mary Jo, primary, Zhang, Jie, primary, Tolaney, Sara M., primary, Cleary, James M., primary, Chen, Alice P., primary, Rubinstein, Lawrence, primary, Boerner, Julie L., primary, Bowditch, Adam, primary, Cai, Dongpo, primary, Bell, Tracy, primary, Wolanski, Andrew, primary, Marrero, Allison M., primary, Zhang, Yiping, primary, Ji, Jiuping, primary, Ferry-Galow, Katherine, primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Methods, Tables S1 and S2, Figure Legend from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Author

Kummar, Shivaani, primary, Oza, Amit M., primary, Fleming, Gini F., primary, Sullivan, Daniel M., primary, Gandara, David R., primary, Naughton, Michael J., primary, Villalona-Calero, Miguel A., primary, Morgan, Robert J., primary, Szabo, Peter M., primary, Youn, Ahrim, primary, Chen, Alice P., primary, Ji, Jiuping, primary, Allen, Deborah E., primary, Lih, Chih-Jian, primary, Mehaffey, Michele G., primary, Walsh, William D., primary, McGregor, Paul M., primary, Steinberg, Seth M., primary, Williams, P. Mickey, primary, Kinders, Robert J., primary, Conley, Barbara A., primary, Simon, Richard M., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Materials from Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity

Author

Pfister, Thomas D., primary, Reinhold, William C., primary, Agama, Keli, primary, Gupta, Shalu, primary, Khin, Sonny A., primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, Tomaszewski, Joseph E., primary, Doroshow, James H., primary, and Pommier, Yves, primary

Published
2023
Full Text
View/download PDF

25. Data from Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Author

Takebe, Naoko, primary, Naqash, Abdul Rafeh, primary, O'Sullivan Coyne, Geraldine, primary, Kummar, Shivaani, primary, Do, Khanh, primary, Bruns, Ashley, primary, Juwara, Lamin, primary, Zlott, Jennifer, primary, Rubinstein, Larry, primary, Piekarz, Richard, primary, Sharon, Elad, primary, Streicher, Howard, primary, Mittra, Arjun, primary, Miller, Sarah B., primary, Ji, Jiuping, primary, Wilsker, Deborah, primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, Chen, Li, primary, Chang, Ting-Chia, primary, Das, Biswajit, primary, Mugundu, Ganesh, primary, Doroshow, James H., primary, and Chen, Alice P., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Methods, Table 1, Figure Legends 1-2 from A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Author

Kummar, Shivaani, primary, Ji, Jiuping, primary, Morgan, Robert, primary, Lenz, Heinz-Josef, primary, Puhalla, Shannon L., primary, Belani, Chandra P., primary, Gandara, David R., primary, Allen, Deborah, primary, Kiesel, Brian, primary, Beumer, Jan H., primary, Newman, Edward M., primary, Rubinstein, Larry, primary, Chen, Alice, primary, Zhang, Yiping, primary, Wang, Lihua, primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, Tomaszewski, Joseph E., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Author

LoRusso, Patricia M., primary, Li, Jing, primary, Burger, Angelika, primary, Heilbrun, Lance K., primary, Sausville, Edward A., primary, Boerner, Scott A., primary, Smith, Daryn, primary, Pilat, Mary Jo, primary, Zhang, Jie, primary, Tolaney, Sara M., primary, Cleary, James M., primary, Chen, Alice P., primary, Rubinstein, Lawrence, primary, Boerner, Julie L., primary, Bowditch, Adam, primary, Cai, Dongpo, primary, Bell, Tracy, primary, Wolanski, Andrew, primary, Marrero, Allison M., primary, Zhang, Yiping, primary, Ji, Jiuping, primary, Ferry-Galow, Katherine, primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data from Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity

Author

Kinders, Robert J., primary, Hollingshead, Melinda, primary, Lawrence, Scott, primary, Ji, Jiuping, primary, Tabb, Brian, primary, Bonner, William M., primary, Pommier, Yves, primary, Rubinstein, Larry, primary, Evrard, Yvonne A., primary, Parchment, Ralph E., primary, Tomaszewski, Joseph, primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

29. Supplemental Figure Legend from A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis

Author

Reiss, Kim A., primary, Herman, Joseph M., primary, Zahurak, Marianna, primary, Brade, Anthony, primary, Dawson, Laura A., primary, Scardina, Angela, primary, Joffe, Caitlin, primary, Petito, Emily, primary, Hacker-Prietz, Amy, primary, Kinders, Robert J., primary, Wang, Lihua, primary, Chen, Alice, primary, Temkin, Sarah, primary, Horiba, Naomi, primary, Siu, Lillian L., primary, and Azad, Nilofer S., primary

Published
2023
Full Text
View/download PDF

30. Supplemental Data from A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

Author

Gojo, Ivana, primary, Beumer, Jan H., primary, Pratz, Keith W., primary, McDevitt, Michael A., primary, Baer, Maria R., primary, Blackford, Amanda L., primary, Smith, B. Douglas, primary, Gore, Steven D., primary, Carraway, Hetty E., primary, Showel, Margaret M., primary, Levis, Mark J., primary, Dezern, Amy E., primary, Gladstone, Douglas E., primary, Ji, Jiuping Jay, primary, Wang, Lihua, primary, Kinders, Robert J., primary, Pouquet, Marie, primary, Ali-Walbi, Ismail, primary, Rudek, Michelle A., primary, Poh, Weijie, primary, Herman, James G., primary, Karnitz, Larry M., primary, Kaufmann, Scott H., primary, Chen, Alice, primary, and Karp, Judith E., primary

Published
2023
Full Text
View/download PDF

31. Supplemental Table 2 from A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis

Author

Reiss, Kim A., primary, Herman, Joseph M., primary, Zahurak, Marianna, primary, Brade, Anthony, primary, Dawson, Laura A., primary, Scardina, Angela, primary, Joffe, Caitlin, primary, Petito, Emily, primary, Hacker-Prietz, Amy, primary, Kinders, Robert J., primary, Wang, Lihua, primary, Chen, Alice, primary, Temkin, Sarah, primary, Horiba, Naomi, primary, Siu, Lillian L., primary, and Azad, Nilofer S., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 3 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Author

LoRusso, Patricia M., primary, Li, Jing, primary, Burger, Angelika, primary, Heilbrun, Lance K., primary, Sausville, Edward A., primary, Boerner, Scott A., primary, Smith, Daryn, primary, Pilat, Mary Jo, primary, Zhang, Jie, primary, Tolaney, Sara M., primary, Cleary, James M., primary, Chen, Alice P., primary, Rubinstein, Lawrence, primary, Boerner, Julie L., primary, Bowditch, Adam, primary, Cai, Dongpo, primary, Bell, Tracy, primary, Wolanski, Andrew, primary, Marrero, Allison M., primary, Zhang, Yiping, primary, Ji, Jiuping, primary, Ferry-Galow, Katherine, primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Data from Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Author

Takebe, Naoko, primary, Naqash, Abdul Rafeh, primary, O'Sullivan Coyne, Geraldine, primary, Kummar, Shivaani, primary, Do, Khanh, primary, Bruns, Ashley, primary, Juwara, Lamin, primary, Zlott, Jennifer, primary, Rubinstein, Larry, primary, Piekarz, Richard, primary, Sharon, Elad, primary, Streicher, Howard, primary, Mittra, Arjun, primary, Miller, Sarah B., primary, Ji, Jiuping, primary, Wilsker, Deborah, primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, Chen, Li, primary, Chang, Ting-Chia, primary, Das, Biswajit, primary, Mugundu, Ganesh, primary, Doroshow, James H., primary, and Chen, Alice P., primary

Published
2023
Full Text
View/download PDF

34. Data from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Author

Kummar, Shivaani, primary, Oza, Amit M., primary, Fleming, Gini F., primary, Sullivan, Daniel M., primary, Gandara, David R., primary, Naughton, Michael J., primary, Villalona-Calero, Miguel A., primary, Morgan, Robert J., primary, Szabo, Peter M., primary, Youn, Ahrim, primary, Chen, Alice P., primary, Ji, Jiuping, primary, Allen, Deborah E., primary, Lih, Chih-Jian, primary, Mehaffey, Michele G., primary, Walsh, William D., primary, McGregor, Paul M., primary, Steinberg, Seth M., primary, Williams, P. Mickey, primary, Kinders, Robert J., primary, Conley, Barbara A., primary, Simon, Richard M., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Author

LoRusso, Patricia M., primary, Li, Jing, primary, Burger, Angelika, primary, Heilbrun, Lance K., primary, Sausville, Edward A., primary, Boerner, Scott A., primary, Smith, Daryn, primary, Pilat, Mary Jo, primary, Zhang, Jie, primary, Tolaney, Sara M., primary, Cleary, James M., primary, Chen, Alice P., primary, Rubinstein, Lawrence, primary, Boerner, Julie L., primary, Bowditch, Adam, primary, Cai, Dongpo, primary, Bell, Tracy, primary, Wolanski, Andrew, primary, Marrero, Allison M., primary, Zhang, Yiping, primary, Ji, Jiuping, primary, Ferry-Galow, Katherine, primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figures 1-2 from A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Author

Kummar, Shivaani, primary, Ji, Jiuping, primary, Morgan, Robert, primary, Lenz, Heinz-Josef, primary, Puhalla, Shannon L., primary, Belani, Chandra P., primary, Gandara, David R., primary, Allen, Deborah, primary, Kiesel, Brian, primary, Beumer, Jan H., primary, Newman, Edward M., primary, Rubinstein, Larry, primary, Chen, Alice, primary, Zhang, Yiping, primary, Wang, Lihua, primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, Tomaszewski, Joseph E., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

38. Data from Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity

Author

Pfister, Thomas D., primary, Reinhold, William C., primary, Agama, Keli, primary, Gupta, Shalu, primary, Khin, Sonny A., primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, Tomaszewski, Joseph E., primary, Doroshow, James H., primary, and Pommier, Yves, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Author

LoRusso, Patricia M., primary, Li, Jing, primary, Burger, Angelika, primary, Heilbrun, Lance K., primary, Sausville, Edward A., primary, Boerner, Scott A., primary, Smith, Daryn, primary, Pilat, Mary Jo, primary, Zhang, Jie, primary, Tolaney, Sara M., primary, Cleary, James M., primary, Chen, Alice P., primary, Rubinstein, Lawrence, primary, Boerner, Julie L., primary, Bowditch, Adam, primary, Cai, Dongpo, primary, Bell, Tracy, primary, Wolanski, Andrew, primary, Marrero, Allison M., primary, Zhang, Yiping, primary, Ji, Jiuping, primary, Ferry-Galow, Katherine, primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

41. Supplemental Figures and Tables from A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia

Author

Pratz, Keith W., primary, Rudek, Michelle A., primary, Gojo, Ivana, primary, Litzow, Mark R., primary, McDevitt, Michael A., primary, Ji, Jiuping, primary, Karnitz, Larry M., primary, Herman, James G., primary, Kinders, Robert J., primary, Smith, B. Douglas, primary, Gore, Steven D., primary, Carraway, Hetty E., primary, Showel, Margaret M., primary, Gladstone, Douglas E., primary, Levis, Mark J., primary, Tsai, Hua-Ling, primary, Rosner, Gary, primary, Chen, Alice, primary, Kaufmann, Scott H., primary, and Karp, Judith E., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 4 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Author

LoRusso, Patricia M., primary, Li, Jing, primary, Burger, Angelika, primary, Heilbrun, Lance K., primary, Sausville, Edward A., primary, Boerner, Scott A., primary, Smith, Daryn, primary, Pilat, Mary Jo, primary, Zhang, Jie, primary, Tolaney, Sara M., primary, Cleary, James M., primary, Chen, Alice P., primary, Rubinstein, Lawrence, primary, Boerner, Julie L., primary, Bowditch, Adam, primary, Cai, Dongpo, primary, Bell, Tracy, primary, Wolanski, Andrew, primary, Marrero, Allison M., primary, Zhang, Yiping, primary, Ji, Jiuping, primary, Ferry-Galow, Katherine, primary, Kinders, Robert J., primary, Parchment, Ralph E., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

44. supplementary figures from Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays

Author

Srivastava, Apurva K., primary, Hollingshead, Melinda G., primary, Weiner, Jennifer, primary, Navas, Tony, primary, Evrard, Yvonne A., primary, Khin, Sonny A., primary, Ji, Jiuping Jay, primary, Zhang, Yiping, primary, Borgel, Suzanne, primary, Pfister, Thomas D., primary, Kinders, Robert J., primary, Bottaro, Donald P., primary, Linehan, W. Marston, primary, Tomaszewski, Joseph E., primary, Doroshow, James H., primary, and Parchment, Ralph E., primary

Published
2023
Full Text
View/download PDF

45. Data from Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity

Author

Kinders, Robert J., primary, Hollingshead, Melinda, primary, Lawrence, Scott, primary, Ji, Jiuping, primary, Tabb, Brian, primary, Bonner, William M., primary, Pommier, Yves, primary, Rubinstein, Larry, primary, Evrard, Yvonne A., primary, Parchment, Ralph E., primary, Tomaszewski, Joseph, primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

46. Supplemental Table 1 from A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis

Author

Reiss, Kim A., primary, Herman, Joseph M., primary, Zahurak, Marianna, primary, Brade, Anthony, primary, Dawson, Laura A., primary, Scardina, Angela, primary, Joffe, Caitlin, primary, Petito, Emily, primary, Hacker-Prietz, Amy, primary, Kinders, Robert J., primary, Wang, Lihua, primary, Chen, Alice, primary, Temkin, Sarah, primary, Horiba, Naomi, primary, Siu, Lillian L., primary, and Azad, Nilofer S., primary

Published
2023
Full Text
View/download PDF

47. Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and density

Author

Somasundaram, Veena, primary, Ridnour, Lisa A., additional, Cheng, Robert YS., additional, Walke, Abigail J., additional, Kedei, Noemi, additional, Bhattacharyya, Dibyangana D., additional, Wink, Adelaide L., additional, Edmondson, Elijah F., additional, Butcher, Donna, additional, Warner, Andrew C., additional, Dorsey, Tiffany H., additional, Scheiblin, David A., additional, Heinz, William, additional, Bryant, Richard J., additional, Kinders, Robert J., additional, Lipkowitz, Stanley, additional, Wong, Stephen TC., additional, Pore, Milind, additional, Hewitt, Stephen M., additional, McVicar, Daniel W., additional, Anderson, Stephen K., additional, Chang, Jenny, additional, Glynn, Sharon A., additional, Ambs, Stefan, additional, Lockett, Stephen J., additional, and Wink, David A., additional

Published
2022
Full Text
View/download PDF

48. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors

Author

Kummar, Shivaani, Chen, Alice, Gutierrez, Martin, Pfister, Thomas D., Wang, Lihua, Redon, Christophe, Bonner, William M., Yutzy, William, Zhang, Yiping, Kinders, Robert J., Ji, Jiuping, Allen, Deborah, Covey, Joseph M., Eiseman, Julie L., Holleran, Julianne L., Beumer, Jan H., Rubinstein, Larry, Collins, Jerry, Tomaszewski, Joseph, Parchment, Ralph, Pommier, Yves, and Doroshow, James H.

Published
2016
Full Text
View/download PDF

50. Interferon-gamma is quintessential for NOS2 and COX2 expression in ER- breast tumors that lead to poor outcome.

Author

Cheng, Robert Y. S., Ridnour, Lisa A., Wink, Adelaide L., Gonzalez, Ana L., Femino, Elise L., Rittscher, Helene, Somasundaram, Veena, Heinz, William F., Coutinho, Leandro, Rangel, M. Cristina, Edmondson, Elijah F., Butcher, Donna, Kinders, Robert J., Li, Xiaoxian, Wong, Stephen T. C., McVicar, Daniel W., Anderson, Stephen K., Pore, Milind, Hewitt, Stephen M., and Billiar, Timothy R.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results